An Open-Label Trial of Duloxetine for the Treatment of Irritable Bowel Syndrome
Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
We hypothesize that duloxetine treatment will be associated with improvement in symptoms of
IBS, particularly abdominal pain, in individuals without comorbid major depressive disorder.
During this 12-week, open-label, outpatient study, male and female subjects between the ages
of 18 and 65 years who have been diagnosed with irritable bowel syndrome (IBS) will be
treated with open-label duloxetine.